TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Bio-Gene Technology Ltd. ( (AU:BGT) ) has provided an announcement.
Bio-Gene Technology Ltd. announced promising results for its Flavocide® product at the International Conference on Lyme Borreliosis and Other Tick-Borne Diseases. Research from Purdue University demonstrated that Flavocide achieved over 90% mortality of Ixodes scapularis nymphs, a major Lyme disease vector, with residual activity lasting up to four weeks. These findings highlight Flavocide’s potential as a novel acaricide for public and animal health, supporting Bio-Gene’s strategy to develop next-generation insecticides. The results open new market opportunities in public health, companion animal, and livestock sectors, addressing the rising incidence of tick-borne diseases.
More about Bio-Gene Technology Ltd.
Bio-Gene Technology Limited is an Australian company focused on developing novel bio-insecticides to tackle global challenges related to insecticide resistance. Their products, derived from natural compounds, aim to control pests effectively while minimizing impacts on human health and the environment. Bio-Gene’s offerings have applications in crop protection, grain storage, public health, and consumer uses, providing safe pest management solutions.
Average Trading Volume: 300,333
Technical Sentiment Signal: Hold
Current Market Cap: A$9.15M
Find detailed analytics on BGT stock on TipRanks’ Stock Analysis page.